Post-earnings recap
Reported
Wed, Nov 14, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Soleno Therapeutics is still in a developmental phase, with no revenue reported. Despite missing EPS expectations, the stock rose by 1.46%, likely due to positive sentiment around future product developments and management's focus on strategic partnerships.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.13 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious optimism regarding future developments. They are focused on advancing their product pipeline and exploring partnerships.
Management emphasized ongoing efforts in product development.
They highlighted the importance of upcoming milestones.
Focus remains on strategic partnerships to enhance growth.